Department of Cell Therapy

The Department of Cell Therapy prepares new gene and cell therapy procedures for clinical application. This involves the validation of experimental approaches with an eye to safety, feasibility and efficiency. Numerous model systems that facilitate the preclinical testing of novel concepts under the strictest quality criteria have been and continue to be established by the department. These systems lend the obtained results a high level of predictive power with regard to their future clinical application. Cell therapeutic methods are used, for instance, in the case of ischemic diseases such as stroke and myocardial infarction while attention is also given to processes that could prevent cell degeneration and aging. The ”sleeping” potential of stem cells is also investigated. Last but not least, the department focuses on cell therapy methods in the field of immuno-oncology, where genetically modified immune cells (cytotoxic T-cells) or natural killer cells (NK cells) are developed to treat tumors.


Experimental Imaging

As technical methods continue to be advanced, new imaging procedures and evaluation methods used to depict structures and processes are always available for biological investigations.


Clinic-oriented Therapy Assessment

The Clinic-oriented Therapy Assessment Unit tests and develops innovative diagnosis and therapy procedures for ischemic stroke. 


Branch Lab Translational Cell Therapy (Hannover)

The Translational Cell Therapy off-site unit develops and validates cell-based advanced therapy medicinal products (ATMPs). To do this, it conducts translational research and develops GMP-compliant manufacturing protocols for cell therapeutics at the interface to preclinical development right through to their transfer into clinical trials.



The EU consortium imSAVAR (Immune Safety Avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies) develops innovative model systems for the evaluation of immunomodulating therapeutics.